AOAbeer Al Otaibi

Abeer Al Otaibi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abeer Al Otaibi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Association of Haptoglobin with Oxidized LDL in Obese Patients with Type 2 Diabetes Mellitus

    by Ahmed Bakillah, Maram Al Subaiee, Khamis Khamees Obeid, Ayman Farouk Soliman, Abeer Al Otaibi, Sindiyan Al Shaikh Mubarak, Yara Abdullah Al Mihmadi, Shahinaz Faisal Bashir, Mohammad Al Arab, Arwa Al Hussaini, et al.

    Background: Cardiovascular disease (CVD) is the leading cause of mortality in obese patients with type 2 diabetes mellitus (T2DM). Conventional biomarkers often fail to detect early endothelial dysfunction and oxidative stress. Haptoglobin (Hp), an acute-phase protein with antioxidant and hemoglobin-binding properties, may indicate vascular injury. While plasma Hp (pl-Hp) reflects systemic inflammation, urinary Hp (u-Hp) could signal renal and microvascular damage. We hypothesize that elevated u-Hp and altered pl-Hp levels are associated with increased oxidized LDL and may serve as sensitive indicators of early vascular injury, thereby identifying obese patients with T2DM at higher cardiovascular risk. This study aims to investigate the associations between u-Hp, pl-Hp, and oxidized LDL (ox-LDL) in obese patients with T2DM, and to evaluate the potential role of Hp as an early biomarker of cardiovascular risk in this high-risk population. Methods and Results: The study included 57 patients with T2DM (mean age 61 ± 10 years, HbA1c 8.66 ± 1.60%, and BMI 35.15 ± 6.65 kg/m2). Notably, 95% of the patients had hypertension, 82% had dyslipidemia, and 59% had an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. Pl-Hp and u-Hp concentrations, as well as ox-LDL levels, were assessed using an enzyme-linked immunosorbent assay (ELISA). Correlations and multivariate regression analyses were employed to investigate the associations between Hp, ox-LDL, and clinical cardiovascular risk factors. Pl-Hp was positively correlated with ox-LDL (r = 0.358, p < 0.006) and negatively correlated with C-reactive protein (CRP) (r = −0.364, p < 0.013), while u-Hp correlated positively with HbA1C and apoB levels (r = 0.298, p < 0.030 and r = 0.310, p < 0.021, respectively). Multivariate analysis indicated that pl-Hp, but not u-Hp, was independently associated with ox-LDL (β = 0.536, p < 0.027) after adjusting for potential confounding factors, including age, gender, BMI, HbA1c, liver enzymes, hs-CRP and creatinine. The Stepwise analysis identified IL-6 as the most significant predictor of cardiovascular disease risk, suggesting its pivotal role in subclinical vascular inflammation among obese individuals with T2DM. Furthermore, the significant positive association between pl-Hp and ox-LDL was stronger in patients with declining renal function as expressed by the estimated glomerular filtration rate (eGFR) (eGFR < 30 mL/min/1.73 m2: β = 2.173, p < 0.031 and eGFR 30–59 mL/min/1.73 m2: β = 1.318, p < 0.002). This association also appeared in early and low-normal ranges of serum albumin: creatinine ratio (s-ACR) (s-ACR < 0.2714 mg/mmol: β = 2.304, p < 0.005 and s-ACR 0.2714–0.3649 mg/mmol: β = 1.000, p < 0.041), suggesting that pl-Hp and ox-LDL rise before overt kidney damage. Elevated IL-6 (≥32.93 pg/mL) further strengthened this link (β = 1.037, p < 0.005), highlighting the role of inflammation in amplifying oxidative stress and acute-phase responses. Conclusions: Taken together, these findings emphasize the interconnected contributions of renal impairment, inflammation, and oxidative stress to vascular injury. While these results need to be confirmed in larger prospective longitudinal studies, monitoring pl-Hp levels in conjunction with inflammatory and kidney function markers could be a sensitive and non-invasive way to identify early CVD risk in high-risk groups, such as obese patients with T2DM.


  • Open Access

    Placenta-Derived Mesenchymal Stem Cells (pMSCs) Reverse Diabetes-Associated Endothelial Complications in a Preclinical Animal Model

    by Yasser Basmaeil, Ahmed Bakillah, Abdullah Mohammed Al Subayyil, Haya Nasser Bin Kulayb, Maha Abdullah AlRodayyan, Abeer Al Otaibi, Sindiyan Al Shaikh Mubarak, Hassan S. Alamri, Altaf A. Kondkar, Jahangir Iqbal, et al.

    Diabetes is increasingly recognized as a chronic inflammatory disease marked by systemic metabolic disturbances, with endothelial dysfunction playing a central role in its complications. Hyperglycemia, a hallmark of diabetes, drives endothelial damage by inducing excessive reactive oxygen species (ROS) production, particularly hydrogen peroxide (H2O2). This oxidative stress impairs endothelial cells, which are vital for vascular health, leading to severe complications such as diabetic nephropathy, retinopathy, and coronary artery disease—major causes of morbidity and mortality in diabetic patients. Recent studies have highlighted the therapeutic potential of placenta-derived mesenchymal stem cells (pMSCs), in mitigating these complications. pMSCs exhibit anti-inflammatory, antioxidant, and tissue-repair properties, showing promise in reversing endothelial damage in laboratory settings. To explore their efficacy in a more physiologically relevant context, we used a streptozotocin (STZ)-induced diabetic mouse model, which mimics type 1 diabetes by destroying pancreatic beta cells and causing hyperglycemia. pMSCs were administered via intra-peritoneal injections, and their effects on endothelial injury and tissue damage were assessed. Metabolic tests, including glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) revealed that pMSCs did not restore metabolic homeostasis or improve glucose regulation. However, histopathological kidney, heart, and eye tissue analyses demonstrated significant protective effects. pMSCs preserved glomerular structure in the kidneys, protected cardiac blood vessels, and maintained retinal integrity, suggesting their potential to address diabetes-related tissue injuries. Although these findings underscore the therapeutic potential of pMSCs for diabetic complications, further research is needed to optimize dosing, elucidate molecular mechanisms, and evaluate long-term safety and efficacy. Combining pMSCs with other therapies may enhance their benefits, paving the way for future clinical applications.

  • Open Access

    Adiponectin and TNF-Alpha Differentially Mediate the Association Between Cystatin C and Oxidized LDL in Type 2 Diabetes Mellitus Patients

    by Ahmed Bakillah, Ayman Farouk Soliman, Maram Al Subaiee, Khamis Khamees Obeid, Arwa Al Hussaini, Shahinaz Faisal Bashir, Mohammad Al Arab, Abeer Al Otaibi, Sindiyan Al Shaikh Mubarak, Ali Ahmed Al Qarni

    In individuals with type 2 diabetes mellitus (T2DM), elevated levels of both plasma and urinary cystatin C (Cys-C) contribute to increased oxidation, which in turn accelerates the oxidation of low-density lipoprotein (LDL). This process may worsen the development of atherosclerosis and cardiovascular disease by promoting endothelial dysfunction and inflammation. Despite its potential significance, the relationship between Cys-C and oxidized LDL (ox-LDL) in T2DM remains poorly understood. This study investigated the relationship between plasma and urinary Cys-C and ox-LDL levels in T2DM patients. The cohort included 57 patients with T2DM (mean age 61.14 ± 9.99 years; HbA1c 8.66 ± 1.60% and BMI 35.15 ± 6.65 kg/m2). Notably, 95% of the patients had hypertension, 82% had dyslipidemia, 59% had an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2, 14% had coronary artery disease (CAD), and 5% had a history of stroke. Plasma and urinary Cys-C and ox-LDL levels were measured using ELISA. Adipokine and cytokine levels were measured using the multiplex® MAP Human Adipokine Magnetic Bead Panels. Spearman’s correlation analysis revealed a significant positive correlation of plasma and urinary Cys-C with ox-LDL (r = 0.569, p = 0.0001 and r = 0.485, p = 0.0001, respectively). Multivariable regression analysis indicated that both plasma and urinary Cys-C were independently associated with ox-LDL, after adjusting for confounding factors (β = 0.057, p = 0.0001 and β = 0.486, p = 0.003, respectively). Stepwise linear regression identified TNFα and adiponectin as the strongest predictors of the relationship between urinary Cys-C and ox-LDL (β = 0.382, p = 0.0001; r2 = 0.64), while adiponectin alone was the best predictor of the plasma Cys-C and ox-LDL association (β = 0.051, p = 0.005; r2 = 0.46). Furthermore, adiponectin partly mediated the relationship between plasma Cys-C and ox-LDL, explaining 18% of the variance in this association. In contrast, TNFα partly mediated the relationship between urinary Cys-C and ox-LDL, accounting for 28% of the variance. This study emphasizes the complex interaction between Cys-C and ox-LDL in T2DM. It highlights the need for additional research involving larger patient cohorts to improve our understanding of the therapeutic potential of plasma and urinary Cys-C in conjunction with ox-LDL for managing complications associated with T2DM.


  • Open Access

    Plasma Atrial Natriuretic Peptide Predicts Oxidized Low-Density Lipoprotein Levels in Type 2 Diabetes Mellitus Patients Independent of Circulating Adipokine and Cytokine

    by Ahmed Bakillah, Maram Al Subaiee, Ayman Farouk Soliman, Khamis Khamees Obeid, Shahinaz Faisal Bashir, Arwa Al Hussaini, Mohammad Al Arab, Abeer Al Otaibi, Sindiyan Al Shaikh Mubarak, Ali Ahmed Al Qarni

    Atrial natriuretic peptide (ANP) and oxidized low-density lipoprotein (ox-LDL) play essential roles in the development and progression of vascular complications associated with type 2 diabetes mellitus (T2DM), and both are independently linked to cardiovascular diseases (CVD). However, the relationship between ANP and ox-LDL in patients with T2DM remains unclear as previous studies have primarily focused on circulating levels in various diseases. This study investigated the relationship between ANP and ox-LDL levels in obese individuals with T2DM. The cohort included 57 patients with T2DM (mean age 61.14 ± 9.99 years; HbA1c 8.66 ± 1.60%; BMI 35.15 ± 6.65 kg/m2). Notably, 95% of the patients had hypertension, 82% had dyslipidemia, 59% had an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2, 14% had coronary artery disease (CAD), and 5% had a history of stroke. Plasma concentrations of ANP and ox-LDL were measured using ELISA. Adipokines and cytokines levels were measured using the multiplex® MAP Human Adipokine Magnetic Beads Spearman’s correlation analysis which revealed a negative correlation between ANP and ox-LDL (r = −0.446, p = 0.001) as well as with the ox-LDL/apoB ratio (r = −0.423, p = 0.001) and ox-LDL/LDLc ratio (r = −0.307, p = 0.038). Multivariable regression analysis indicated that ANP was independently associated with ox-LDL (β = −115.736, p = 0.005). Stepwise linear regression further identified TNFα, leptin, and adiponectin as the strongest predictors influencing the relationship between ANP and ox-LDL levels (β = −64.664, p = 0.0311, and r2 = 0.546 for the model). However, these factors did not significantly mediate this association. This study emphasizes the need for further exploration of the complex interaction between ANP and ox-LDL in larger patient populations. This could provide valuable insights into potential therapeutic approaches for managing vascular complications in obese individuals with T2DM.